by Lloyd Billingsley via American Greatness,
“My position was just tell the American public the truth. There are side effects to vaccines. Tell them the truth and don’t try to package it.”
That was Dr. Robert Redfield, director of the Centers for Disease Control during the administration of Donald Trump.
Ford Motor has announced layoffs of 600 workers at its Michigan assembly plant, related to the United Auto Workers (UAW) union strike, CNBC reported on Friday.
At Ford's Michigan Assembly Plant in Wayne, Michigan, dozens of UAW members were picketing the factory's main entrance on Friday, and many rued changes to their contract and work rules over the past 15 years that especially cut new "Tier II" hires at lower wages and reduced benefits.
https://finance.yahoo.com/news/1-ford-announces-600-job-203555371.html
Canada plans to amend its competition laws to enable the regulator to act against anti-competitive mergers in the grocery sector, as the government steps up efforts to battle rising food prices.
Canadian Prime Minister Justin Trudeau on Thursday said he had summoned the heads of Canada's top grocers to Ottawa next week to discuss their plans to control food prices.
The government could impose new taxes on the grocery chains if they do not provide a convincing plan to limit the rise of food prices, Trudeau said.
The amendments will also provide the Competition Bureau with powers to compel the production of information to conduct effective market studies, a release, dated Sept. 14, from the Prime Minister's Office said.
GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.
The London-based pharmaceutical maker explained that "nearly all" myelofibrosis patients are estimated to develop anaemia over the course of the disease, with over 30% discontinuing treatment due to anaemia.
GSK said, to date, it is the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients with anaemia that addresses the key manifestations of the disease, namely anaemia, constitutional symptoms, and splenomegaly, or an enlarged spleen.
"The vast majority of myelofibrosis patients eventually develop anaemia, causing them to discontinue treatments and require transfusions. Given this high unmet need, we are proud to add Ojjaara to our oncology portfolio and address a significant medical need in the community," said Nina Mojas, senior vice president of Oncology Global Product Strategy at GSK.
Myelofibrosis is a blood cancer. It can lead to severely low blood counts, including anaemia and thrombocytopaenia, a condition in which platelets are low in number.
The US Food & Drug Administration has approved the drug for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, in adults with anaemia.
The FDA approval is supported by data from the Momentum study and a subpopulation of adult patients with anaemia from the Simplify-1 phase three trial.
The Momentum study was designed to evaluate the safety and efficacy of momelotinib versus danazol for the treatment and reduction of key manifestations of myelofibrosis in an anaemic, symptomatic, JAK inhibitor-experienced patients. It met all its primary and key secondary endpoints.
Simplify-1 was designed to evaluate the efficacy and safety of momelotinib versus ruxolitinib in myelofibrosis patients who had not received a prior JAK-inhibitor therapy.
Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Neumora. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neumora, are expected to be approximately $250 million. In addition, Neumora has granted the underwriters a 30-day option to purchase up to 2,206,500 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on September 15, 2023 under the ticker symbol “NMRA.” The initial public offering is expected to close on September 19, 2023, subject to the satisfaction of customary closing conditions.
J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets, and William Blair are acting as joint book-running managers for the offering.
https://finance.yahoo.com/news/neumora-therapeutics-announces-pricing-initial-004900392.html
European regulators voted against fully approving a Duchenne muscular dystrophy treatment from PTC Therapeutics (PTCT), and PTC stock crashed Friday.
In morning trades on today's stock market, PTC shares collapsed 27.8% to 27.
The Committee for Medicine Products for Human Use for the European Medicines Agency issued a negative opinion of the PTC drug, Translarna, for patients with the muscle-weakening disease.
The advisors also voted against renewing the conditional approval for Translarna. Conditional approval allows a medicine to be fast-tracked for approval while still under testing. But the drugmaker must continue testing the drug to prove its benefit. The European advisors says PTC's evidence didn't pass muster.
"We are surprised and extremely disappointed by the CHMP decision, given the well-established and favorable safety and (effectiveness) profile of Translarna," Chief Executive Matthew Klein said in a written statement.
